Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial

Johan A. Maertens, Issam I. Raad, Kieren A. Marr, Thomas F. Patterson, Dimitrios P. Kontoyiannis, Oliver A. Cornely, Eric J. Bow, Galia Rahav, Dionysios Neofytos, Mickael Aoun, John W. Baddley, Michael Giladi, Werner J. Heinz, Raoul Herbrecht, William Hope, Meinolf Karthaus, Dong Gun Lee, Olivier Lortholary, Vicki A. Morrison, Ilana OrenDominik Selleslag, Shmuel Shoham, George Richard Thompson, Misun Lee, Rochelle M. Maher, Anne Hortense Schmitt-Hoffmann, Bernhardt Zeiher, Andrew J. Ullmann

Research output: Contribution to journalArticlepeer-review

400 Scopus citations

Fingerprint

Dive into the research topics of 'Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial'. Together they form a unique fingerprint.

Medicine & Life Sciences